SCHEMBL13629321

SCHEMBL13629321

COc1ccc(CNc2ccc3cnc4ncc(Cl)cc4c(=O)c3c2)c(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 3/20 0.50
MAPT P10636 4/20 0.46
GAA P10253 2/20 0.46
ERBB2 P04626 1/20 0.45
PRKACA P17612 1/20 0.45
RPS6KB1 P23443 1/20 0.45
GSK3A P49840 1/20 0.45
GSK3B P49841 1/20 0.45
IRAK1 P51617 1/20 0.45
RPS6KA3 P51812 1/20 0.45
ROCK1 Q13464 1/20 0.45
CDC42BPA Q5VT25 1/20 0.45
AURKB Q96GD4 1/20 0.45
CSNK1G3 Q9Y6M4 1/20 0.45
FGFR3 P22607 1/20 0.44
KDR P35968 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 3/20 0.42
CYP1A2 P05177 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2326254 0.89 DHFR (0.55) DHFRMAPTGAAERBB2PRKACA
SCHEMBL13859971 0.82 DHFR (0.51) DHFRMAPTGAAERBB2PRKACA
SCHEMBL4318574 0.82 CYP1A2 (0.46) DHFRERBB2PRKACARPS6KB1GSK3A
SCHEMBL4467541 0.81 NPC1 (0.42) MAPTALDH1A1CYP3A4TDP1KDM4E
SCHEMBL2327489 0.75 MET (0.57) DHFRFGFR3KDRMEN1KMT2A
SCHEMBL2449081 0.73 MET (0.59) DHFRMEN1KMT2AALDH1A1CYP1A2
SCHEMBL2326620 0.72 MET (0.58) DHFRMAPTGAAFGFR3KDR
SCHEMBL2449039 0.72 DHFR (0.49) DHFRMAPTGAAERBB2PRKACA
SCHEMBL2326096 0.72 DHFR (0.49) DHFRMAPTGAAERBB2PRKACA
SCHEMBL2446907 0.72 CYP1A2 (0.51) DHFRFGFR3KDRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291941-A1 Tyrosine Kinase Inhibitors MERCK SHARP & DOHME CORP. 2009-11-26 US disclosed
US-20090291941-A1 Tyrosine Kinase Inhibitors MERCK SHARP & DOHME CORP. 2009-11-26 US disclosed
WO-2007050401-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291941-A1 Tyrosine Kinase Inhibitors ABL1, ERBB2, RET DHFR 448/4885MAPT 3080/4885GAA 1423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.